ATAI Life Sciences Overview

  • Founded
  • 2018
Founded
  • Status
  • IPO Registration
  • Employees
  • 65
Employees
  • Latest Deal Type
  • IPO
  • (Announced)
  • Latest Deal Amount
  • $200M
Latest Deal Amount
  • Investors
  • 43

ATAI Life Sciences General Information

Description

Operator of a biotechnology company intended to develop drugs for anxiety and depression treatment. The company's drugs are made of psilocybin mushroom that contains psychedelic prodrug compound which helps to disrupt the sorts of engrained brain activity patterns and alleviate anxiety in cancer patients, enabling people to live longer healthier and happier lives.

Contact Information

Website
www.atai.life
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • C/o Mindspace
  • Krausenstraße 9-10
  • 10117 Berlin
  • Germany
+49 089 00000000

ATAI Life Sciences Timeline

201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ATAI Life Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. IPO 20-Apr-2021 $200M 00000 00.000 Announced Clinical Trials - Phase 2
5. Later Stage VC (Series D) 03-Mar-2021 00000 00000 000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 23-Nov-2020 00000 00000 00000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 27-Mar-2019 0000 000.00 00000 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 04-Oct-2018 $29.1M $42.4M 00000 Completed Generating Revenue
1. Seed Round 01-Jan-2018 $13.3M $13.3M Completed Startup
To view ATAI Life Sciences’s complete valuation and funding history, request access »

ATAI Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology company intended to develop drugs for anxiety and depression treatment. The company's drugs
Drug Discovery
Berlin, Germany
65 As of 2021
00000
0.000 0000-00-00
00000000 00000

000000 0

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000 000000000
Boston, MA
00 As of 0000
00000
00000000000 00000

0000 000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000000000000
Cambridge, MA
000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ATAI Life Sciences Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Karuna Therapeutics Formerly VC-backed Boston, MA 00 00000 00000000000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
000000 00000000000 Corporation New York, NY 00 000.00 00000000 000.00
You’re viewing 3 of 3 competitors. Get the full list »

ATAI Life Sciences Executive Team (11)

Name Title Board Seat Contact Info
Florian Brand Co-Founder, Chief Executive Officer & Board Member
Ryan Barrett JD General Counsel and Lead, Corporate Development
Aaron Weaver Senior General Counsel and Lead Investor Relations
Danny Talati Lead, Business Development
Rolando Gutierrez-Esteinou MD Chief Medical Officer
You’re viewing 5 of 11 executive team members. Get the full list »

ATAI Life Sciences Board Members (4)

Name Representing Role Since
Florian Brand ATAI Life Sciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Gregory Weaver Self Chief Financial Officer & Board Member 000 0000
Jason Camm Self Board Member 000 0000
Julien Höfer ATAI Life Sciences Chairman of Supervisory Board 000 0000
To view ATAI Life Sciences’s complete board members history, request access »

ATAI Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ATAI Life Sciences Investors (43)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Deep End Partners Venture Capital Minority 000 0000 000000 0
Fearless Ventures Venture Capital Minority 000 0000 000000 0
Highline Capital Management Hedge Fund Minority 000 0000 000000 0
JLS Fund Venture Capital Minority 000 0000 000000 0
Palo Santo Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 43 investors. Get the full list »

ATAI Life Sciences Investments & Acquisitions (15)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 14-May-2021 0000 0000 Drug Delivery 0000000 00000
000000 07-Apr-2021 000000000000000000 Therapeutic Devices 000000000 0000000000
000000000 0000 000 06-Nov-2020 000000000000000000 Biotechnology 00000000 000 00.0
00000 09-Jul-2020 000000000000000000 Drug Discovery 0000000 00000
COMPASS Pathways 17-Apr-2020 Early Stage VC 000.00 Drug Discovery 0000000 00000
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

ATAI Life Sciences Subsidiaries (2)

Company Name Industry Location Founded
Kures Drug Discovery Dobbs Ferry, NY 2017
000000 Therapeutic Devices New York, NY
To view ATAI Life Sciences’s complete subsidiaries history, request access »

ATAI Life Sciences Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 00000000 17-Apr-2020 00000 00000 00 000.00 Completed
  • 17 buyers
0000000 00000000 20-Sep-2018 00000 00000 00 000.00 Completed
  • 5 buyers
COMPASS Pathways Corporate 000.00 Completed
To view ATAI Life Sciences’s complete exits history, request access »